Potentially useful markers for desmoplastic melanoma: An analysis of KBA.62, p-AKT, and ezrin

American Journal of Dermatopathology

Volumn 33, Issue 4, 2011, Pages 333-340

  Bernaba, Bob N ^a   Vogiatzis, Prokopis I ^b   Binder, Scott W ^a   Cassarino, David S ^c  

^a UCLA MEDICAL CENTER   (United States)

^b METAXA CANCER HOSPITAL   (Greece)

^c KAISER PERMANENTE   (United States)

Author keywords

desmoplastic melanoma; ezrin; KBA.62; melanoma; p AKT

Indexed keywords

BIOLOGICAL MARKER; EZRIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KBA.62; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; DESMOPLASTIC MELANOMA; DIFFERENTIAL DIAGNOSIS; EXCISION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; NERVE SHEATH TUMOR; PERIPHERAL NERVE SHEATH TUMOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR CELL; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CELL COUNT; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; MALE; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-AKT; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79958295681     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181e5a2b4     Document Type: Article

References (28)

1. Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer. 1998;83:1128-1135. (Pubitemid 28419065)
2. Busam KJ, Mujumdar U, Hummer AJ, et al. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol. 2004;28:1518-1525. (Pubitemid 39425520)
3. Lens MB, Newton-Bishop JA, Boon AP. Desmoplastic malignant melanoma: a systematic review. Br J Dermatol. 2005;152:673-678. (Pubitemid 40571298)
4. Anstey A, McKee P,Wilson-Jones E. Desmoplastic malignant melanoma: a clinicopathologic study of 25 cases. Br J Dermatol. 1993;129:359-371. (Pubitemid 23308236)
5. Carlson JA, Dickersin GR, Sober AJ, et al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of26cases.Cancer. 1995;75:478-494.
6. Skelton HG, Smith KJ, Laskin WB, et al. Desmoplastic malignant melanoma. J Am Acad Dermatol. 1995;32:717-725.
7. Egbert B, Kempson R, Sagebiel R. Desmoplastic malignant melanoma. A clinicohistopathologic study of 25 cases. Cancer. 1988;62:2033-2041. (Pubitemid 18261833)
8. Troxel DB. Pitfalls in the diagnosis of malignant melanoma: findings of a risk management panel study. Am J Surg Pathol. 2003;27:1278-1283. (Pubitemid 37040591)
9. Arbiser ZK, Folpe AL, Weiss SW. Consultative (expert) second opinions in soft tissue pathology. Am J Clin Pathol. 2001;116:473-476.
10. de Almeida LS, Requena L, Rü tten A, et al. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases. Am J Dermatopathol. 2008;30:207-215.
11. Jain S, Allen PW. Desmoplastic malignant melanoma and its variants. A study of 45 cases. Am J Surg Pathol. 1989;13:358-373. (Pubitemid 19134066)
12. Kaneishi NK, Cockerell CJ. Histologic differentiation of desmoplastic melanoma from cicatrices. Am J Dermatopathol. 1998;20:128-134. (Pubitemid 28164959)
13. McCarthy SW, Scolyer RA, Palmer AA. Desmoplastic melanoma: a diagnostic trap for the unwary. Pathology. 2004;36:445-451. (Pubitemid 39273988)
14. Ohsie SJ, Sarantopoulos GP, Cochran AJ, et al. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35:433-444. (Pubitemid 351519417)
15. Busam KJ, Iversen K, Coplan KC, et al. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol. 2001;25: 197-204. (Pubitemid 32167501)
16. Chorny JA, Barr RJ. S100-positive spindle cells in scars: a diagnostic pitfall in the re-excision of desmoplastic melanoma. Am J Dermatopathol. 2002;24:309-312. (Pubitemid 34810306)
17. Nonaka D, Chiriboga L, Rubin BP. Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. J Cutan Pathol. 2008;35:1014-1019.
18. Kanik AB, Yaar M, Bhawan J. p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma. J Cutan Pathol. 1996;23:205-210. (Pubitemid 26181307)
19. Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer. 1971;28:914-936.
20. Cohen-Knafo E, al Saati T, Aziza J, et al. Production and characterisation of an antimelanoma monoclonal antibody KBA.62 using a new melanoma cell line reactive on paraffin wax embedded sections. J Clin Pathol. 1995; 48:826-831.
21. Pagès C, Rochaix P, al Saati T, et al. KBA.62: a useful marker for primary and metastatic melanomas. Hum Pathol. 2008;39:1136-1142.
22. Gould KL, Bretscher A, Esch FS, et al. cDNA cloning and sequencing of the protein-tyrosine kinase substrate, ezrin, reveals homology to band 4.1. EMBO J. 1989;8:4133-4142. (Pubitemid 20066856)
23. Bretscher A, Reczek D, Berryman M. Ezrin: a protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures. J Cell Sci. 1997;110:3011-3018. (Pubitemid 28026432)
24. Aoki M, Batista O, Bellacosa A, et al. The Akt kinase: Molecular determinants of oncogenicity. Proc Natl Acad Sci USA. 1998;95:14950-14955. (Pubitemid 29003737)
25. Franke TF, Kaplan DR, Cantley LC. PI3K:Downstream AKTion blocks apoptosis. Cell. 1997;88:435-437.
26. Ilmonen S, Vaheri A, Asko-Seljavaara S, et al. Ezrin in primary cutaneous melanoma. Mod Pathol. 2005;18:503-510. (Pubitemid 40478113)
27. Kantrow SM, Boyd AS, Ellis DL, et al. Expression of activated Akt in benign nevi, Spitz nevi and melanomas. J Cutan Pathol. 2007;34:593-596. (Pubitemid 47063230)
28. Slipicevic A, Holm R, Nguyen MT, et al. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol. 2005;124:528-536. (Pubitemid 41395633)